Dr. Glaucomflecken Explains: Rituximab versus Ocrelizumab in Relapsing Multiple Sclerosis @NEJMgroup

Uploaded August 2026 | Updated September 2026, 1 week ago

This video in our partnership with @DGlaucomflecken explains a head-to-head trial comparing rituximab versus ocrelizumab in newly diagnosed relapsing multiple sclerosis. Access the full results of the OVERLORD-MS trial for free: https://nej.md/DrG46

#neurology #medicaleducation #NEJM

Dr. Glaucomflecken Explains: Rituximab versus Ocrelizumab in Relapsing Multiple Sclerosis

Could a Low-Plastic Lifestyle Lower Plastic Levels in our Body?

Three Studies That Made Headlines in May

Dr. Glaucomflecken Explains: Intensive LDL Cholesterol Targeting in Atherosclerotic CVD (Ez-PAVE)

Clinical Problem-Solving: Too Much of a Good Thing

NEJM Clinician: Are PPIs Linked to COPD Flares?

Naomi T. Nkinsi, MD, MPH, on Racial Bias in Diagnosing Kidney Disease

Aaron Baugh, MD, on Race-Specific Equations for Lung Function

NEJM Interview: Lawrence Casalino on qualities of corporate organizations that could affect physi...

Improvements in Hearing and Speech Perception after Gene Therapy and Contralateral Cochlear Implant